Abstract:Objectives: Long-term hepatitis B virus (HBV) infection can cause recurrent inflammation in the liver, and then develop into liver fibrosis, cirrhosis, and liver cancer. The hepatic pathological change is one of the important criteria for guiding antiviral therapy in patients with chronic hepatitis B (CHB). Due to the limitations of liver biopsy, it is necessary to find valuable non-invasive indicators to evaluate the hepatic pathological changes in CHB patients and guide the antiviral therapy. This study aims to analyze the clinical characteristics of different pathological changes in CHB patients, and to explore the factors influnencing the degree of liver inflammation and fibrosis in CHB patients with normal alanine aminotransferase (ALT). Methods: This retrospective study was conducted on 310 CHB patients. Liver biopsy was performed in all these patients. The clinical data of the patients were collected. The liver biopsy pathological results were used as the gold standard to analyze the relationship between clinical indicators and liver pathological changes. Then CHB patients with normal ALT were screened, and the independent factors influencing the degree of liver inflammation and fibrosis were explored. Results: Among the 310 patients with CHB, there were 249 (80.3%) patients with significant liver inflammation [liver inflammation grade (G) ≥2] and 119 (38.4%) patients with significant liver fibrosis [liver fibrosis stage (S) ≥2]. The results of univariate analysis of total samples showed that the ALT, γ-glutamyl transferase, alkaline phosphatase, and HBV DNA were related to the significant liver pathological changes. Among the 132 CHB patients with normal ALT, the patients with liver pathology G/S≥2, G≥2, and S≥2 were 80.3% (106/132), 68.2% (90/132), and 43.2% (57/132), respectively. The results showed that the independent influencing factor of significant liver inflammation was HBV DNA>2 000 U/mL (OR=3.592, 95% CI 1.534 to 8.409), and the independent influencing factors of significant liver fibrosis were elevated alkaline phosphatase level (OR=1.022, 95% CI 1.002 to 1.043), decreased platelet count (OR=0.990, 95% CI 0.982 to 0.998), and positive in hepatitis B e antigen (HBeAg) (OR=14.845, 95% CI 4.898 to 44.995). According to the multivariate analysis, a diagnostic model for significant liver fibrosis in CHB patients with normal ALT was established, and the area under the receiver operating characteristic curve was 0.844 (95% CI 0.779 to 0.910). Conclusions: The liver pathological changes should be evaluated in combination with different clinical indicators. A considerable number of CHB patients with normal ALT still have significant liver pathological changes, which need to be identified and treated with antiviral therapy in time. Among them, HBV DNA>2 000 U/mL suggests the significant liver inflammation, and the diagnostic model for significant liver fibrosis based on alkaline phosphatase, platelet count, and HBeAg can help to evaluate the degree of liver fibrosis.

Natural course of subjects with elevated liver tests and normal liver histology

Insight into the natural history of primary biliary cirrhosis: A systemic review of data from placebo-controlled clinical trials.

Non-ALT Biomarkers for Markedly Abnormal Liver Histology among Chinese Persistently Normal Alanine Aminotransferase-Chronic Hepatitis B Patients.

The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years

Natural History of Hepatitis B E Antigen to Antibody Seroconversion in Patients with Normal Serum Aminotransferase Levels

Hepatobiliary manifestations in patients with ulcerative colitis: a retrospective analysis

Natural History of Liver Disease in a Large International Cohort of Children with Alagille Syndrome: Results from the GALA Study

Brief Communication: Clinical Implications of Short-Term Variability in Liver Function Test Results

Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study

Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design

Clinicopathological analysis of non-alcoholic steatohepatitis

Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity

Clinical Significance of Liver Biopsy in Diagnosis of Non-Viral Liver Diseases

Histological features of chronic hepatitis B patients with normal alanine aminotransferase according to different criteria

Significant Liver Histological Change is Common in HBeAg-positive Chronic Hepatitis B with Normal ALT

Non-invasive alloimmune risk stratification of long-term liver transplant recipients

Liver Biopsy: To Do or Not to Do - A Single-Center Study

P- 37 CLINICAL EVOLUTION OF PATIENTS WITH AUTOIMMUNE LIVER DISEASES IN A LIVER TRANSPLANTATION CENTER

Study on liver histopathology of chronic HBV infected patients with different normal ALT values

Clinicopathologic characteristics of liver inflammation and fibrosis in 310 patients with chronic hepatitis B

Long-term outcomes of patients with autoimmune hepatitis induced cirrhosis after immunosuppressive treatment